JP2014531441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531441A5 JP2014531441A5 JP2014530260A JP2014530260A JP2014531441A5 JP 2014531441 A5 JP2014531441 A5 JP 2014531441A5 JP 2014530260 A JP2014530260 A JP 2014530260A JP 2014530260 A JP2014530260 A JP 2014530260A JP 2014531441 A5 JP2014531441 A5 JP 2014531441A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- hexyl
- amino
- phenylcarbamoyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzyloxy, phenyl Chemical group 0.000 claims description 34
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 10
- FZXCPFJMYOQZCA-BYPYZUCNSA-N (2s)-6-oxopiperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCC(=O)N1 FZXCPFJMYOQZCA-BYPYZUCNSA-N 0.000 claims description 3
- AMOCDUAYMXFIHU-DLBZAZTESA-N (2R)-N-[(2S)-1-anilino-7-ethoxycarbothioyloxy-1-oxoheptan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound O=C1CC[C@@H](N1)C(=O)N[C@@H](CCCCCOC(OCC)=S)C(NC1=CC=CC=C1)=O AMOCDUAYMXFIHU-DLBZAZTESA-N 0.000 claims description 2
- NEGLYSNZRMUEHF-ZEQRLZLVSA-N (2s)-6-oxo-n-[(2s)-1-oxo-1-[(3-phenylmethoxyphenyl)methylamino]-7-sulfanylheptan-2-yl]piperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NCC=1C=C(OCC=2C=CC=CC=2)C=CC=1)C(=O)[C@@H]1CCCC(=O)N1 NEGLYSNZRMUEHF-ZEQRLZLVSA-N 0.000 claims description 2
- QVHKENDYYOPWET-IRXDYDNUSA-N (2s)-6-oxo-n-[(2s)-1-oxo-7-sulfanyl-1-[[4-(trifluoromethyl)phenyl]methylamino]heptan-2-yl]piperidine-2-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)[C@H](CCCCCS)NC(=O)[C@H]1NC(=O)CCC1 QVHKENDYYOPWET-IRXDYDNUSA-N 0.000 claims description 2
- JTIATMCBWUQBGH-IRXDYDNUSA-N (2s)-n-[(2s)-1-(3-methylanilino)-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound CC1=CC=CC(NC(=O)[C@H](CCCCCS)NC(=O)[C@H]2NC(=O)CCC2)=C1 JTIATMCBWUQBGH-IRXDYDNUSA-N 0.000 claims description 2
- PVOSRCQGYUSIRG-IRXDYDNUSA-N (2s)-n-[(2s)-1-(4-methylanilino)-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound C1=CC(C)=CC=C1NC(=O)[C@H](CCCCCS)NC(=O)[C@H]1NC(=O)CCC1 PVOSRCQGYUSIRG-IRXDYDNUSA-N 0.000 claims description 2
- QNJCPEYHBKCISJ-OALUTQOASA-N (2s)-n-[(2s)-1-[2-(3-methylphenyl)ethylamino]-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound CC1=CC=CC(CCNC(=O)[C@H](CCCCCS)NC(=O)[C@H]2NC(=O)CCC2)=C1 QNJCPEYHBKCISJ-OALUTQOASA-N 0.000 claims description 2
- PLWFKMKFFURSPO-IRXDYDNUSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-1-methyl-6-oxopiperidine-2-carboxamide Chemical compound C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCS)C(=O)NC1=CC=CC=C1 PLWFKMKFFURSPO-IRXDYDNUSA-N 0.000 claims description 2
- NYJOCLMLIASQTH-HOTGVXAUSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 NYJOCLMLIASQTH-HOTGVXAUSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-PCCBWWKXSA-N (3r,4r)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@H]2[C@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-PCCBWWKXSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-QHAWAJNXSA-N (3r,4s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@@H]2[C@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-QHAWAJNXSA-N 0.000 claims description 2
- ILCBWDQDWOLKIQ-HOTGVXAUSA-N (3s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxopiperidine-3-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCNC1=O ILCBWDQDWOLKIQ-HOTGVXAUSA-N 0.000 claims description 2
- UHKDIMIVZUCWEH-HKBOAZHASA-N (3s,4s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@@H]2[C@@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-HKBOAZHASA-N 0.000 claims description 2
- FFAADXOKPZHULO-UHFFFAOYSA-N 2-methylpropanethioic s-acid Chemical compound CC(C)C(S)=O FFAADXOKPZHULO-UHFFFAOYSA-N 0.000 claims description 2
- ILCBWDQDWOLKIQ-CVEARBPZSA-N N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCNC1=O Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCNC1=O ILCBWDQDWOLKIQ-CVEARBPZSA-N 0.000 claims description 2
- DPCLRUJQAZJUFQ-RBUKOAKNSA-N s-[(6s)-7-(3-methylanilino)-6-[[(2r)-1-methyl-5-oxopyrrolidine-2-carbonyl]amino]-7-oxoheptyl] ethanethioate Chemical compound C1CC(=O)N(C)[C@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC(C)=C1 DPCLRUJQAZJUFQ-RBUKOAKNSA-N 0.000 claims description 2
- FZVCUTATXGHVOB-ZWKOTPCHSA-N s-[(6s)-7-(3-methylanilino)-7-oxo-6-[[(2r)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=C(C)C=CC=1)C(=O)[C@H]1CCC(=O)N1 FZVCUTATXGHVOB-ZWKOTPCHSA-N 0.000 claims description 2
- QGYPCQAYENIOOF-DLBZAZTESA-N s-[(6s)-7-anilino-7-oxo-6-[[(2r)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCC(=O)N1 QGYPCQAYENIOOF-DLBZAZTESA-N 0.000 claims description 2
- QGYPCQAYENIOOF-IRXDYDNUSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCC(=O)N1 QGYPCQAYENIOOF-IRXDYDNUSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- YYSCXBPFYMVUDP-LSDHHAIUSA-N (2R)-N-[(2S)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-5-oxopyrrolidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCC(=O)N1 YYSCXBPFYMVUDP-LSDHHAIUSA-N 0.000 claims 1
- NYJOCLMLIASQTH-CVEARBPZSA-N (2R)-N-[(2S)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCC(=O)N1 NYJOCLMLIASQTH-CVEARBPZSA-N 0.000 claims 1
- LZODJSNRNSCPJV-KBPBESRZSA-N (2s)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-4-oxoazetidine-2-carboxamide Chemical compound N([C@@H](CCCCCS)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CC(=O)N1 LZODJSNRNSCPJV-KBPBESRZSA-N 0.000 claims 1
- UOQRZCNCICUPJO-IUCAKERBSA-N (3s,4r)-2-oxo-4-phenylpyrrolidine-3-carboxylic acid Chemical compound C1NC(=O)[C@@H](C(=O)O)[C@@H]1C1=CC=CC=C1 UOQRZCNCICUPJO-IUCAKERBSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- BIBVHLRGWUFEHW-OALUTQOASA-N C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 Chemical compound C1CCC(=O)N(C)[C@@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 BIBVHLRGWUFEHW-OALUTQOASA-N 0.000 claims 1
- JMVYSWLYZWSUMX-WMZOPIPTSA-N CC(=O)SCCCCC[C@@H](C(=O)NC1CCCC1)NC(=O)[C@@H]2C(=O)CCCN2 Chemical compound CC(=O)SCCCCC[C@@H](C(=O)NC1CCCC1)NC(=O)[C@@H]2C(=O)CCCN2 JMVYSWLYZWSUMX-WMZOPIPTSA-N 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- STZNXPSZBFZZRC-LBPRGKRZSA-N SCCCCC[C@H](N)C(=O)NC1=CC=CC=C1 Chemical compound SCCCCC[C@H](N)C(=O)NC1=CC=CC=C1 STZNXPSZBFZZRC-LBPRGKRZSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 1
- 235000008206 alpha-amino acids Nutrition 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- MYXNWWDJRWCURH-UHFFFAOYSA-N ethoxymethanethioic s-acid Chemical compound CCOC(S)=O MYXNWWDJRWCURH-UHFFFAOYSA-N 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000004303 peritoneum Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- CTDAROLPRDFAMC-OALUTQOASA-N s-[(6s)-7-(3-methylanilino)-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=C(C)C=CC=1)C(=O)[C@@H]1CCCC(=O)N1 CTDAROLPRDFAMC-OALUTQOASA-N 0.000 claims 1
- QYGBXTVUZBVNKJ-OALUTQOASA-N s-[(6s)-7-(4-methylanilino)-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC(C)=CC=1)C(=O)[C@@H]1CCCC(=O)N1 QYGBXTVUZBVNKJ-OALUTQOASA-N 0.000 claims 1
- FNRKKVARQRBUKS-ROUUACIJSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2s)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 FNRKKVARQRBUKS-ROUUACIJSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- PUENFUNUWKSIGX-ROUUACIJSA-N (2S)-N-[(2S)-1-anilino-7-ethoxycarbothioyloxy-1-oxoheptan-2-yl]-6-oxopiperidine-2-carboxamide Chemical compound N([C@@H](CCCCCOC(=S)OCC)C(=O)NC=1C=CC=CC=1)C(=O)[C@@H]1CCCC(=O)N1 PUENFUNUWKSIGX-ROUUACIJSA-N 0.000 description 1
- FZXCPFJMYOQZCA-SCSAIBSYSA-N (2r)-6-oxopiperidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCC(=O)N1 FZXCPFJMYOQZCA-SCSAIBSYSA-N 0.000 description 1
- YSPMLLKKKHCTBN-REOHCLBHSA-N (2s)-4-oxoazetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=O)N1 YSPMLLKKKHCTBN-REOHCLBHSA-N 0.000 description 1
- UHKDIMIVZUCWEH-ACRUOGEOSA-N (3s,4r)-n-[(2s)-1-anilino-1-oxo-7-sulfanylheptan-2-yl]-2-oxo-4-phenylpyrrolidine-3-carboxamide Chemical compound C1([C@H]2[C@@H](C(NC2)=O)C(=O)N[C@@H](CCCCCS)C(=O)NC=2C=CC=CC=2)=CC=CC=C1 UHKDIMIVZUCWEH-ACRUOGEOSA-N 0.000 description 1
- QOXLRWMTGBTFSF-GJZGRUSLSA-N N([C@@H](CCCCCS)C(=O)NC1CCCC1)C(=O)[C@@H]1CCCC(=O)N1 Chemical compound N([C@@H](CCCCCS)C(=O)NC1CCCC1)C(=O)[C@@H]1CCCC(=O)N1 QOXLRWMTGBTFSF-GJZGRUSLSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DMUPSHHTOQXMGA-ZWKOTPCHSA-N s-[(6s)-7-anilino-6-[[(2r)-1-methyl-5-oxopyrrolidine-2-carbonyl]amino]-7-oxoheptyl] ethanethioate Chemical compound C1CC(=O)N(C)[C@H]1C(=O)N[C@@H](CCCCCSC(C)=O)C(=O)NC1=CC=CC=C1 DMUPSHHTOQXMGA-ZWKOTPCHSA-N 0.000 description 1
- FNRKKVARQRBUKS-MSOLQXFVSA-N s-[(6s)-7-anilino-7-oxo-6-[[(2r)-6-oxopiperidine-2-carbonyl]amino]heptyl] ethanethioate Chemical compound N([C@@H](CCCCCSC(=O)C)C(=O)NC=1C=CC=CC=1)C(=O)[C@H]1CCCC(=O)N1 FNRKKVARQRBUKS-MSOLQXFVSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181832.4 | 2011-09-19 | ||
| EP11181832 | 2011-09-19 | ||
| PCT/EP2012/068230 WO2013041480A1 (en) | 2011-09-19 | 2012-09-17 | New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014531441A JP2014531441A (ja) | 2014-11-27 |
| JP2014531441A5 true JP2014531441A5 (enExample) | 2016-08-18 |
| JP6053795B2 JP6053795B2 (ja) | 2016-12-27 |
Family
ID=46888433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530260A Active JP6053795B2 (ja) | 2011-09-19 | 2012-09-17 | 強力なｈｄａｃ阻害剤としてのラクタムを有する新しいチオ誘導体、及び治療剤としてのその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8927533B2 (enExample) |
| EP (1) | EP2758371B1 (enExample) |
| JP (1) | JP6053795B2 (enExample) |
| KR (1) | KR101929774B1 (enExample) |
| CN (1) | CN103732577B (enExample) |
| AU (1) | AU2012311640B2 (enExample) |
| BR (1) | BR112014006600B1 (enExample) |
| CA (1) | CA2843211C (enExample) |
| DK (1) | DK2758371T3 (enExample) |
| EA (1) | EA023171B1 (enExample) |
| ES (1) | ES2579321T3 (enExample) |
| HU (1) | HUE029687T2 (enExample) |
| IL (1) | IL230717A (enExample) |
| MX (1) | MX369508B (enExample) |
| NZ (1) | NZ620336A (enExample) |
| PH (1) | PH12014500249A1 (enExample) |
| PL (1) | PL2758371T3 (enExample) |
| PT (1) | PT2758371T (enExample) |
| UA (1) | UA111231C2 (enExample) |
| WO (1) | WO2013041480A1 (enExample) |
| ZA (1) | ZA201402790B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2806258T3 (es) * | 2013-12-03 | 2021-02-17 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| WO2016201374A1 (en) * | 2015-06-11 | 2016-12-15 | University Of Florida Research Foundation, Incorporated | Sulfanide adenosine derivatives and uses thereof |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| IT1244507B (it) * | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| MXPA02002505A (es) * | 1999-09-08 | 2004-09-10 | Sloan Kettering Inst Cancer | Nueva clase de agentes de citodiferenciacion e inhibidores de histona desacetilasa y metodos de utilizacion de los mismos. |
| ITRM20010464A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
| US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1694640A4 (en) * | 2003-11-28 | 2007-01-10 | Univ Queensland | ANTI CANCER AGENTS |
| US20080194524A1 (en) * | 2003-12-19 | 2008-08-14 | Jerini Ag | Compounds For the Inhibition of Undesired Cell Proliferation and Use Thereof |
| JP2007238452A (ja) | 2006-03-03 | 2007-09-20 | Nippon Kayaku Co Ltd | ヒストン脱アセチル化酵素を阻害する新規化合物 |
| EP2100879A1 (en) * | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
-
2012
- 2012-09-17 HU HUE12761967A patent/HUE029687T2/en unknown
- 2012-09-17 CN CN201280039630.9A patent/CN103732577B/zh active Active
- 2012-09-17 UA UAA201404167A patent/UA111231C2/uk unknown
- 2012-09-17 KR KR1020147003177A patent/KR101929774B1/ko active Active
- 2012-09-17 US US14/236,359 patent/US8927533B2/en active Active
- 2012-09-17 BR BR112014006600-0A patent/BR112014006600B1/pt active IP Right Grant
- 2012-09-17 CA CA2843211A patent/CA2843211C/en active Active
- 2012-09-17 PL PL12761967T patent/PL2758371T3/pl unknown
- 2012-09-17 PT PT127619674T patent/PT2758371T/pt unknown
- 2012-09-17 DK DK12761967.4T patent/DK2758371T3/en active
- 2012-09-17 MX MX2014003334A patent/MX369508B/es active IP Right Grant
- 2012-09-17 EA EA201400365A patent/EA023171B1/ru unknown
- 2012-09-17 WO PCT/EP2012/068230 patent/WO2013041480A1/en not_active Ceased
- 2012-09-17 PH PH1/2014/500249A patent/PH12014500249A1/en unknown
- 2012-09-17 JP JP2014530260A patent/JP6053795B2/ja active Active
- 2012-09-17 AU AU2012311640A patent/AU2012311640B2/en not_active Ceased
- 2012-09-17 EP EP12761967.4A patent/EP2758371B1/en active Active
- 2012-09-17 ES ES12761967.4T patent/ES2579321T3/es active Active
- 2012-09-17 NZ NZ620336A patent/NZ620336A/en not_active IP Right Cessation
-
2014
- 2014-01-29 IL IL230717A patent/IL230717A/en active IP Right Grant
- 2014-04-16 ZA ZA2014/02790A patent/ZA201402790B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500681C2 (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
| JP2017533968A5 (enExample) | ||
| MY165906A (en) | Phenothiazine diaminium salts and their use | |
| JP2015505296A5 (enExample) | ||
| JP2016526558A5 (enExample) | ||
| JP2015516420A5 (enExample) | ||
| JP2013510885A5 (enExample) | ||
| JP2014521625A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| JP2018511590A5 (enExample) | ||
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EP4328223A3 (en) | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| JP2011132222A5 (enExample) | ||
| JP2013523802A5 (enExample) | ||
| HRP20170736T1 (hr) | Indoli | |
| JP2015514063A5 (enExample) | ||
| UA114405C2 (uk) | Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу | |
| JP2005539045A5 (enExample) | ||
| KR101929774B1 (ko) | 락탐을 강력한 hdac 억제제로서 보유하는 신규 티오 유도체 및 약제로서 그의 용도 | |
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот | |
| JP2018530582A5 (enExample) | ||
| JP2016522195A5 (enExample) | ||
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2016537432A5 (enExample) |